AfricaRegulatory
African Pharmaceutical Regulatory Intelligence
DESVENLAFAXINE SUCCINATE
5 registrations across 3 African markets— 5 active
Markets with DESVENLAFAXINE SUCCINATE
Recent registrations
| Brand / Product | Market | Holder | Status | Expires |
|---|---|---|---|---|
| VENLAFIX-100 Tablet | 🇰🇪Kenya | HIRAL LABS LIMITED | active | Apr 2028 |
| DESLAFAXOR 50 (EXTENDED RELEASE) TABLET, COATED; ORAL | 🇿🇼Zimbabwe | INNOVATA PHARMACEUTICALS LTD | active | Dec 2027 |
| DESLAFAXOR 100 (EXTENDED RELEASE) TABLET, COATED; ORAL | 🇿🇼Zimbabwe | INNOVATA PHARMACEUTICALS LTD | active | Dec 2027 |
| EXSIRA 100 mg | 🇿🇦South Africa | Pfizer Laboratories (Pty) Ltd | active | Jan 1900 |
| EXSIRA 50 mg | 🇿🇦South Africa | Pfizer Laboratories (Pty) Ltd | active | Jan 1900 |
DESVENLAFAXINE SUCCINATE in Africa — Regulatory Overview
DESVENLAFAXINE SUCCINATE is registered across 3 African markets with 5 total product registrations on file. Data is sourced directly from official national drug regulatory authorities including South Africa, Zimbabwe, Kenya. AfricaRegulatory refreshes this data daily from official government sources.
Of the 5 registrations, 5 (100%) are currently active. Regulatory affairs teams use AfricaRegulatory to track registration expiry dates, identify market incumbents, and monitor approval status across African markets without manual monitoring of each national regulator.